COMT and GAD1 gene polymorphisms are associated with impaired antisaccade task performance in schizophrenic patients

Genetic influences modulating executive functions engaging prefrontal cortical brain systems were investigated in 141 male subjects. The effects of variations in two genes implicated in dopamine and GABA activities in the prefrontal cortex: rs4680 (Val158/Met polymorphism of the catechol-o-methyltransferase gene—COMT) and rs3749034 (C/T) substitution in the promoter region of the glutamic acid decarboxylase gene (GAD1) were studied on antisaccade (AS) performance in healthy subjects and schizophrenic patients. Genotyping revealed a trend towards a reduced proportion of COMT Val/Met heterozygotes and a significantly increased frequency of the GAD1 rs3749034 C allele in schizophrenic patients relative to controls. Patients had elevated error rates, increased AS latencies and increased latency variability (coefficient of variation) compared to controls. The influence of polymorphisms was observed only in patients but not in controls. A substantial effect of the COMT genotype was noted on the coefficient of variation in latency, and this measure was higher in Val homozygotes compared to Met allele carriers (p < 0.05) in the patient group. The outcome from rs3749034 was also disclosed on the error rate (higher in T carriers relative to C homozygotes, p < 0.01) and latency (increased in C homozygotes relative to T carriers, p < 0.01). Binary logistic regression showed that inclusion of the genotype factor (i.e., selective estimation of antisaccade measures in CC carriers) considerably increased the validity of the diagnostic model based on the AS measures. These findings may well be derived from specific genetic associations with prefrontal cortex functioning in schizophrenia

What's next for the neurobiology of temperament, personality and psychopathology?

This paper represents the outcome of a multidisciplinary discussion on what works, what doesn't, and what can be improved, in on-going work on bio-behavioural taxonomies and their biomarkers. The authors of this paper, representing a wide spectrum of bio-behavioural disciplines (clinical, developmental, differential psychology, neurophysiology, endocrinology, psychiatry, neurochemistry, neurosciences), have contributed more extensive opinions to the Theme Issue "Neurobiology of temperament, personality and psychopathology: what's next?". The authors identified ten directions in international and multidisciplinary cooperation, and multiple insights for "what is next" for each of these directions

What is next for the neurobiology of temperament, personality and psychopathology?

This paper represents the outcome of a multidisciplinary discussion on what works, what does not, and what can be improved, in ongoing work on biobehavioral taxonomies and their biomarkers. The authors of this paper, representing a wide spectrum of biobehavioral disciplines (clinical, developmental, differential psychology, neurophysiology, endocrinology, psychiatry, neurochemistry, and neurosciences), have contributed more extensive opinions to the Theme Issue 'Neurobiology of temperament, personality and psychopathology: what's next?'. The authors identified 10 directions in international and multidisciplinary cooperation, and multiple insights for ‘what is next’ for each of these directions